Atezolizumab was the first to demonstrate a significant enhancement in the survival of patients with advanced lung cancer who have an intolerance to platinum-based chemotherapy (14), irrespective of the type of pathology, PD-L1 expression, or PS score. The gene discussed is CD274; the disease is lung cancer.